|View printer-friendly version|
|Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy|
– Andrew Dickinson Promoted to Executive Vice President, Corporate
Development and Strategy;
Mr. Dickinson joined Gilead in 2016 as Senior Vice President, Corporate
Development. He led the acquisitions of
“Andy has brought to Gilead vision, creativity and leadership,
fundamentally changing the way that we assess and execute acquisitions
and partnerships as an organization,” said
Dr. Silverstein will remain at Gilead through the end of August, working with Mr. Dickinson and other leaders to transition his duties.
“I’m grateful to Marty for his exceptional work to strengthen Gilead’s strategic planning and vision, and ensure that we are well-positioned for future growth, as we seek to bring the next generation of medicines forward for patients with unmet medical needs,” said Dr. Milligan. “We understand his decision to eliminate the bicoastal schedule he has kept since joining Gilead and be closer to his family, and wish him the very best in the next phase of his career.”
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties, and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.
Minimum 20 minute delay